MMMT
MCID: CRC021
MIFTS: 61

Carcinosarcoma (MMMT)

Categories: Bone diseases, Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Carcinosarcoma

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma 12 52 54 43 15
Malignant Mixed Mullerian Tumor 12 52
Mixed Tumor, Mesodermal 43 17
Mixed Tumor, Mullerian 52 43
Mmmt 12 52
Malignant Mixed Mesodermal Tumor 12
Malignant Mixed Müllerian Tumor 74
Mixed Mesodermal Tumor 12
Mesodermal Mixed Tumor 12
Mullerian Mixed Tumor 12
Mixed Müllerian Tumor 74
Mixed Mullerian Tumor 52
Mixed Tumor Mullerian 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4236
SNOMED-CT 67 63264007 84427001
UMLS 71 C0007140 C0206627 C1334603

Summaries for Carcinosarcoma

NIH Rare Diseases : 52 A malignant mixed mullerian tumor (MMMT) , also called a carcinosarcoma , is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary : Carcinosarcoma, also known as malignant mixed mullerian tumor, is related to ovarian carcinosarcoma and primary peritoneal carcinoma. An important gene associated with Carcinosarcoma is VIM (Vimentin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include breast, uterus and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia : 74 A malignant mixed Mullerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer... more...

Related Diseases for Carcinosarcoma

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 841)
# Related Disease Score Top Affiliating Genes
1 ovarian carcinosarcoma 34.8 TP53 PPP2R1A PIK3CA ERBB2
2 primary peritoneal carcinoma 33.1 TP53 PGR ERBB2
3 rare tumor 31.8 KIT DES ACTC1
4 adenomyoma 31.7 PGR MUC1 MME KRT7 CTNNB1
5 adenosarcoma 31.4 VIM TP53 PGR MME MB KIT
6 spindle cell sarcoma 31.2 VIM MUC1 KRT7 DES ACTC1
7 fibrous histiocytoma 31.2 VIM DES ACTC1
8 undifferentiated pleomorphic sarcoma 31.1 PIK3CA KRAS KIT
9 transitional cell carcinoma 31.0 TP53 PTEN KRT7 HRAS ERBB2
10 fibrosarcoma 31.0 VIM TP53 KIT DES ACTC1
11 malignant fibroxanthoma 30.9 VIM MUC1 DES ACTC1
12 neuroendocrine carcinoma 30.9 PTEN MUC1 KRT7 KIT
13 bilateral breast cancer 30.9 PTEN PIK3CA PGR ERBB2
14 uterine carcinosarcoma 30.9 VIM U2AF1 TP53 S100A1 PTEN PPP2R1A
15 pulmonary blastoma 30.9 TP53 KRAS DES
16 thymoma, familial 30.8 KIT HRAS
17 spindle cell carcinoma 30.8 VIM PGR MUC1 KRT7 HRAS DES
18 krukenberg carcinoma 30.8 MUC1 KRT7
19 malignant spiradenoma 30.8 TP53 KRT7
20 botryoid rhabdomyosarcoma 30.8 MB DES ACTC1
21 bizarre leiomyoma 30.7 TP53 PGR ACTC1
22 mesenchymal cell neoplasm 30.7 TP53 MME KIT
23 thyroid gland anaplastic carcinoma 30.7 TP53 PTEN PIK3CA
24 histiocytoma 30.7 VIM TP53 MB KIT ACTC1
25 breast metaplastic carcinoma 30.7 PGR KRT7 ERBB2
26 eccrine porocarcinoma 30.6 VIM MUC1 KRT7
27 in situ carcinoma 30.6 TP53 PTEN PGR MUC1 HRAS ERBB2
28 ovarian serous carcinoma 30.6 TP53 KRAS ERBB2
29 testicular germ cell tumor 30.6 TP53 PTEN KIT HRAS
30 embryonal sarcoma 30.6 VIM TP53 KIT DES CTNNB1
31 adenoma 30.6 TP53 PIK3CA MUC1 KRT7 KRAS CTNNB1
32 adrenocortical carcinoma, hereditary 30.6 TP53 PIK3CA CTNNB1
33 medulloepithelioma 30.6 VIM KRT7 DES
34 clear cell adenocarcinoma 30.5 TP53 PIK3CA PGR KRT7
35 large cell neuroendocrine carcinoma 30.5 PGR KRT7 KIT ERBB2
36 mesenchymoma 30.5 MB KIT DES
37 mucinous cystadenocarcinoma 30.5 VIM MUC1 KRT7 ACTC1
38 thyroid carcinoma 30.5 TP53 PTEN PIK3CA HRAS CTNNB1
39 spindle cell thymoma 30.4 MUC1 DES
40 thyroid gland follicular carcinoma 30.4 TP53 PTEN HRAS
41 brooke-spiegler syndrome 30.4 VIM TP53 KRT7
42 papillary serous adenocarcinoma 30.4 TP53 PGR KRT7 KRAS
43 cystic teratoma 30.4 TP53 PTEN KRT7 KRAS KIT
44 mature teratoma 30.4 TP53 KRT7 KRAS KIT ERBB2
45 small cell carcinoma 30.4 TP53 PTEN MUC1 KRT7 KRAS KIT
46 vulvar intraepithelial neoplasia 30.4 TP53 CTNNB1
47 embryonal rhabdomyosarcoma 30.4 TP53 MB HRAS DES
48 lung benign neoplasm 30.4 TP53 KRT7 KRAS HRAS
49 adenomatoid tumor 30.3 VIM KRT7 DES
50 adrenal cortical carcinoma 30.3 VIM TP53 MUC1 CTNNB1 ACTC1

Graphical network of the top 20 diseases related to Carcinosarcoma:



Diseases related to Carcinosarcoma

Symptoms & Phenotypes for Carcinosarcoma

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.23 HRAS KRAS MUC1 PIK3CA
2 Decreased viability GR00106-A-0 10.23 KRAS
3 Decreased viability GR00221-A-1 10.23 HRAS KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.23 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.23 HRAS
6 Decreased viability GR00221-A-4 10.23 PIK3CA
7 Decreased viability GR00301-A 10.23 KRAS
8 Decreased viability GR00381-A-1 10.23 KRAS
9 Decreased viability GR00402-S-2 10.23 HRAS KRAS MUC1 PIK3CA
10 Decreased viability in esophageal squamous lineage GR00235-A 9.97 CTNNB1 DES ERBB2 HRAS KIT KRAS
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.87 CTNNB1 ERBB2 HRAS MUC1 PPP2R1A PTEN
12 Decreased cell migration GR00055-A-1 9.85 CTNNB1 HRAS KRAS MUC1 PIK3CA VIM
13 Increased cell death HMECs cells GR00103-A-0 9.43 CTNNB1 PGR PIK3CA PPP2R1A PTEN TP53
14 Reduced mammosphere formation GR00396-S 9.23 DES HRAS KRAS KRT7 POLE PPP2R1A

MGI Mouse Phenotypes related to Carcinosarcoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 CTNNB1 DES ERBB2 HRAS KIT KRAS
2 homeostasis/metabolism MP:0005376 10.36 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
3 cellular MP:0005384 10.35 ACTC1 CTNNB1 DES ERBB2 KIT KRAS
4 cardiovascular system MP:0005385 10.34 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
5 mortality/aging MP:0010768 10.2 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
6 embryo MP:0005380 10.16 CTNNB1 ERBB2 KIT KRAS MB PGR
7 integument MP:0010771 10.14 CTNNB1 ERBB2 HRAS KIT KRAS MME
8 muscle MP:0005369 10.07 ACTC1 CTNNB1 DES ERBB2 KIT KRAS
9 limbs/digits/tail MP:0005371 9.91 CTNNB1 ERBB2 KIT KRAS PGR PTEN
10 neoplasm MP:0002006 9.9 CTNNB1 ERBB2 HRAS KIT KRAS PGR
11 normal MP:0002873 9.7 ACTC1 CTNNB1 ERBB2 HRAS KIT KRAS
12 respiratory system MP:0005388 9.32 CTNNB1 ERBB2 HRAS KIT KRAS MB

Drugs & Therapeutics for Carcinosarcoma

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 127)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Mesna Approved, Investigational Phase 3 3375-50-6 598
8
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
9
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
10
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
11
Histamine Approved, Investigational Phase 3 51-45-6 774
12
Cyproheptadine Approved Phase 3 129-03-3 2913
13 Albumin-Bound Paclitaxel Phase 3
14 Antimitotic Agents Phase 3
15 Antibiotics, Antitubercular Phase 3
16 Anti-Bacterial Agents Phase 3
17 Antineoplastic Agents, Immunological Phase 3
18 Alkylating Agents Phase 3
19 Angiogenesis Inhibitors Phase 3
20
Isophosphamide mustard Phase 3 0
21 Topoisomerase Inhibitors Phase 3
22 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
23
Liposomal doxorubicin Phase 2, Phase 3 31703
24 Gastrointestinal Agents Phase 3
25 Neurotransmitter Agents Phase 3
26 Dermatologic Agents Phase 3
27 Antipruritics Phase 3
28 Histamine H1 Antagonists Phase 3
29 Serotonin Agents Phase 3
30 Histamine Antagonists Phase 3
31
Histamine Phosphate Phase 3 51-74-1 65513
32 Serotonin Antagonists Phase 3
33 Anti-Allergic Agents Phase 3
34
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
35
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
36
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
39
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
40
Durvalumab Approved, Investigational Phase 2 1428935-60-7
41
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
42
Metformin Approved Phase 2 657-24-9 14219 4091
43
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
44
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
45
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
46
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
47
Etoposide Approved Phase 2 33419-42-0 36462
48
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
49
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
50
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Unknown status NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
2 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
3 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
4 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
5 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
7 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
8 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
9 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
11 A Randomised Feasibility Study of Extended Chemotherapy With Neoadjuvant Carboplatin, Then Surgery Followed by Adjuvant Paclitaxel and Gemcitabine Verses Neoadjuvant Gemcitabine and Carboplatin, Then Surgery, Followed by Adjuvant Paclitaxel Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
12 A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
13 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
14 A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
15 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
16 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
17 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
18 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
19 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
20 Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
21 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
22 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
23 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
24 A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
25 Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
26 A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
27 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
28 Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin Completed NCT00006005 Phase 2 thalidomide
29 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
30 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
31 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
32 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
33 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
34 Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
35 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
36 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
37 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
38 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
39 A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma Recruiting NCT03395080 Phase 2 Paclitaxel;300mg DKN-01;600mg DKN-01
40 A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
41 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
42 An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma Recruiting NCT03694262 Phase 2 Rucaparib;Bevacizumab;Atezolizumab
43 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Recruiting NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
44 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
45 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
46 A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion Recruiting NCT03933761 Phase 2 Pamiparib
47 A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer Recruiting NCT04034927 Phase 2 Olaparib
48 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
49 A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy. Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
50 Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer Recruiting NCT03241745 Phase 2 Nivolumab

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Genetic Tests for Carcinosarcoma

Anatomical Context for Carcinosarcoma

MalaCards organs/tissues related to Carcinosarcoma:

40
Breast, Uterus, Lung, Ovary, Liver, Prostate, Bone

Publications for Carcinosarcoma

Articles related to Carcinosarcoma:

(show top 50) (show all 3831)
# Title Authors PMID Year
1
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. 54 61
20189232 2010
2
Intraductal carcinosarcoma with a heterologous mesenchymal component originating in intraductal papillary-mucinous carcinoma (IPMC) of the pancreas with both carcinoma and osteosarcoma cells arising from IPMC cells. 54 61
20203229 2010
3
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. 54 61
19200930 2009
4
Carcinosarcoma of the gallbladder producing alpha-fetoprotein and manifesting as leukocytosis with elevated serum granulocyte colony-stimulating factor: report of a case. 54 61
19280285 2009
5
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. 54 61
16648864 2006
6
Carcinosarcoma of the liver producing granulocyte-colony stimulating factor. 54 61
16792552 2006
7
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 54 61
16140564 2006
8
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. 54 61
16157366 2006
9
Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. 54 61
15950966 2005
10
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. 54 61
15894930 2005
11
Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases. 54 61
15863125 2005
12
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 54 61
15901136 2005
13
ERBB-2 gene overexpression and amplification in uterine sarcomas. 54 61
15581967 2004
14
Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. 54 61
15223963 2004
15
Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. 54 61
12604887 2003
16
Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. 54 61
12218209 2002
17
Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. 54 61
11687977 2001
18
Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. 54 61
11180164 2001
19
Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation. 54 61
9786352 1998
20
Uterine angiosarcomas: a morphologic and immunohistochemical study of four cases. 54 61
9500227 1998
21
Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy. 54 61
9313326 1997
22
Immunohistochemical study of the histogenesis of esophageal carcinosarcoma. 54 61
1283991 1992
23
Effects of staurosporine, K 252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. 54 61
1457347 1992
24
Thymic carcinosarcoma associated with a spindle cell thymoma: an immunohistochemical study. 54 61
1398523 1992
25
Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas. 54 61
1612579 1992
26
Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. 54 61
1672262 1991
27
Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. 54 61
2201434 1990
28
An immunohistological comparison of primary lung carcinosarcoma and sarcoma. 54 61
1696005 1990
29
Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling. 61
31876640 2020
30
Carcinosarcoma (adenocarcinoma, neuroendocrine carcinoma, undifferentiated carcinoma and chondrosarcoma) of the gallbladder. 61
31264080 2020
31
Clinical outcome and comparison between squamous and non-squamous cell carcinoma of the larynx. 61
31852360 2020
32
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. 61
31833974 2020
33
Squamous cell carcinoma with sarcomatoid differentiation or carcinosarcoma of the uterine cervix associated with HPV33 infection: report of a rare case. 61
32035484 2020
34
Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary. 61
31796530 2020
35
Clinicopathological characteristics and survival outcomes in breast carcinosarcoma: A SEER population-based study. 61
31812891 2020
36
A Case of Carcinosarcoma of the Gastroesophageal Junction With Neuroendocrine and Chondroid Differentiation. 61
30955394 2020
37
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. 61
32029291 2020
38
A rare case of cutaneous basal cell carcinosarcoma in an immunosuppressed patient. 61
31918851 2020
39
Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. 61
31789001 2020
40
Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review. 61
31934920 2020
41
Evaluation of treatment results and prognostic factors of uterine sarcoma: A single-center experience. 61
31517774 2020
42
Carcino-sarcoma of the urinary bladder with cartilaginous differentiation: About a case report. 61
31681537 2020
43
Cutaneous pilomatrical carcinosarcoma: a case report with molecular analysis and literature review. 61
32005258 2020
44
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. 61
31765263 2020
45
Adjuvant chemotherapy in endometrial cancer. 61
31950214 2020
46
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86). 61
31992589 2020
47
DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. 61
31768620 2020
48
Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report. 61
31848313 2020
49
Pulmonary carcinosarcoma: analysis from the Surveillance, Epidemiology and End Results database. 61
31518405 2020
50
Hepatobiliary and pancreatic: A case of stone-like carcinosarcoma of the common bile duct. 61
31943369 2020

Variations for Carcinosarcoma

Cosmic variations for Carcinosarcoma:

9 (show top 50) (show all 522)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87905773 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 6
2 COSM87899223 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 6
3 COSM87898818 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 6
4 COSM87905366 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
5 COSM87901171 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
6 COSM145422024 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 6
7 COSM91381505 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 6
8 COSM88349172 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 6
9 COSM92365507 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 6
10 COSM90833519 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 6
11 COSM87152527 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 6
12 COSM87132544 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 6
13 COSM87145727 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 6
14 COSM87139234 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 6
15 COSM97107326 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 6
16 COSM97107379 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 6
17 COSM87804005 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 6
18 COSM87804055 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 12:25245350-25245350 6
19 COSM88586417 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 6
20 COSM86804346 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 6
21 COSM86804352 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 6
22 COSM86808602 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 6
23 COSM86751503 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 6
24 COSM86769580 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 6
25 COSM86757992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 6
26 COSM86757673 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 6
27 COSM86757974 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 6
28 COSM86770841 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827= 7:55191730-55191730 6
29 COSM86748127 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 6
30 COSM86751403 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 6
31 COSM86757983 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744= 7:55174769-55174769 6
32 COSM86761167 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 6
33 COSM86751510 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 6
34 COSM86780270 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704= 7:55173971-55173971 6
35 COSM86767926 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 6
36 COSM86755734 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853= 7:55191808-55191808 6
37 COSM86770885 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 6
38 COSM86805588 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 6
39 COSM88138689 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 6
40 COSM97820944 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 6
41 COSM133536287 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 6
42 COSM148939078 ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 6
43 COSM111761369 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
44 COSM142841902 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
45 COSM122736483 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 6
46 COSM147950776 ovary,NS,carcinoma,adenocarcinoma c.*163A>G p.? 7:55174032-55174032 6
47 COSM111980548 ovary,NS,carcinoma,adenocarcinoma c.2462A>G p.E821G 7:55191846-55191846 6
48 COSM145024458 ovary,NS,carcinoma,adenocarcinoma c.425G>A p.R142H 17:7675070-7675070 6
49 COSM121879352 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 6
50 COSM139858573 ovary,NS,carcinoma,adenocarcinoma c.695-1G>C p.? 18:47848688-47848688 6

Expression for Carcinosarcoma

Search GEO for disease gene expression data for Carcinosarcoma.

Pathways for Carcinosarcoma

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 VIM TP53 S100A1 PTEN PPP2R1A PIK3CA
2
Show member pathways
13.85 VIM TP53 PTEN PPP2R1A MUC1 KRAS
3
Show member pathways
13.54 PPP2R1A PIK3CA KRT7 KRAS KIT HRAS
4
Show member pathways
13.48 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
5
Show member pathways
13.39 VIM TP53 PPP2R1A PIK3CA MUC1 KRAS
6
Show member pathways
13.31 VIM PPP2R1A KRAS KIT HRAS ERBB2
7
Show member pathways
12.99 TP53 PTEN PIK3CA KRAS HRAS CTNNB1
8
Show member pathways
12.93 PTEN PIK3CA KRAS HRAS ERBB2 CTNNB1
9
Show member pathways
12.89 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
10
Show member pathways
12.84 TP53 PTEN PIK3CA KRAS KIT HRAS
11 12.8 TP53 KRAS KIT HRAS ERBB2
12 12.8 TP53 PTEN PIK3CA KRAS KIT HRAS
13
Show member pathways
12.77 PIK3CA KRAS KIT HRAS CTNNB1
14
Show member pathways
12.74 TP53 PTEN PIK3CA KRAS HRAS ERBB2
15
Show member pathways
12.71 TP53 PTEN PIK3CA KRAS HRAS ERBB2
16
Show member pathways
12.67 TP53 PTEN PIK3CA KRAS HRAS ERBB2
17
Show member pathways
12.63 VIM PTEN PIK3CA KRAS HRAS
18
Show member pathways
12.63 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
19
Show member pathways
12.61 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
20 12.56 VIM MUC1 KRT7 DES ACTC1
21
Show member pathways
12.53 TP53 PTEN PIK3CA KRAS HRAS ERBB2
22
Show member pathways
12.52 PTEN PIK3CA KRAS HRAS ERBB2
23 12.49 VIM TP53 PTEN PIK3CA KRAS HRAS
24
Show member pathways
12.48 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
25
Show member pathways
12.48 TP53 PTEN PIK3CA PGR KRAS KIT
26
Show member pathways
12.43 TP53 PTEN PIK3CA HRAS
27
Show member pathways
12.43 PIK3CA KRAS KIT HRAS ERBB2 CTNNB1
28
Show member pathways
12.4 PPP2R1A PIK3CA PGR KRAS
29 12.39 TP53 PTEN PIK3CA KRAS HRAS
30
Show member pathways
12.36 PTEN PIK3CA KRAS HRAS
31
Show member pathways
12.36 TP53 PIK3CA MUC1 KRAS HRAS ERBB2
32 12.32 TP53 PIK3CA KRAS HRAS
33
Show member pathways
12.32 PIK3CA KRAS HRAS ERBB2
34
Show member pathways
12.3 PPP2R1A PIK3CA KRAS HRAS
35 12.3 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
36
Show member pathways
12.26 TP53 PTEN PIK3CA KRAS HRAS ERBB2
37 12.22 PTEN KRAS HRAS ERBB2
38 12.22 TP53 PTEN PIK3CA KRAS HRAS
39
Show member pathways
12.21 TP53 PIK3CA KRAS HRAS
40
Show member pathways
12.2 PTEN PIK3CA KIT HRAS
41
Show member pathways
12.19 PTEN PIK3CA KRAS HRAS ERBB2
42 12.18 TP53 PTEN KRAS CTNNB1
43
Show member pathways
12.17 TP53 PIK3CA KRAS HRAS
44
Show member pathways
12.17 PTEN PIK3CA HRAS ERBB2 CTNNB1
45 12.13 PIK3CA KRAS HRAS CTNNB1
46
Show member pathways
12.11 PTEN PIK3CA KRAS HRAS
47 12.11 PTEN PIK3CA KRAS HRAS
48 12.05 TP53 PIK3CA KRAS HRAS CTNNB1
49 12 TP53 PTEN KRAS HRAS CTNNB1
50
Show member pathways
11.98 PIK3CA PGR KRAS HRAS ERBB2

GO Terms for Carcinosarcoma

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.13 VIM PTEN PPP2R1A POLE PIK3CA MUC1
2 extracellular exosome GO:0070062 9.91 VIM PPP2R1A MUC1 MME MB KRT7
3 cytosol GO:0005829 9.8 VIM TP53 PTEN PPP2R1A PIK3CA PGR
4 focal adhesion GO:0005925 9.55 VIM MME KRAS CTNNB1 ACTC1
5 cytoplasm GO:0005737 9.55 VIM TP53 S100A1 PTEN PPP2R1A PIK3CA
6 fascia adherens GO:0005916 9.37 DES CTNNB1

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.85 PTEN KRAS KIT HRAS ERBB2 CTNNB1
2 Ras protein signal transduction GO:0007265 9.65 TP53 KRAS HRAS
3 heart development GO:0007507 9.65 TP53 PTEN MB ERBB2 CTNNB1
4 positive regulation of MAPK cascade GO:0043410 9.62 KIT HRAS ERBB2 CTNNB1
5 muscle filament sliding GO:0030049 9.58 VIM DES ACTC1
6 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.46 TP53 MUC1
7 positive regulation of MAP kinase activity GO:0043406 9.46 KRAS KIT HRAS ERBB2
8 response to isolation stress GO:0035900 9.43 KRAS HRAS
9 cytokine-mediated signaling pathway GO:0019221 9.43 VIM TP53 PIK3CA MUC1 KRAS KIT
10 positive regulation of gene expression GO:0010628 9.28 VIM TP53 PTEN KRAS KIT HRAS

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 VIM TP53 S100A1 PTEN PGR ERBB2
2 protein binding GO:0005515 9.58 VIM U2AF1 TP53 S100A1 PTEN PPP2R1A
3 protein C-terminus binding GO:0008022 9.46 TP53 HRAS ERBB2 CTNNB1
4 nucleotide binding GO:0000166 9.35 POLE KRAS KIT HRAS ERBB2

Sources for Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....